 Revenue from four Canadian clinics increased 80.3 to 407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up infusions at new Montreal clinic Advancing three funded clinical trials through Braxia Scientifics network of clinics, including a Ketamine trial for Bipolar Depression, a Ketamine trial to rapidly reduce suicidality, and the first multiple-dose psilocybin trial to combat treatment-resistant depression TORONTO, Aug. 30, 2021 PRNewswire - Braxia Scientific Corp. Braxia Scientific, or the Company, CSE: BRAX OTC: BRAXF FWB: 496, a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal first-quarter results for the three-month period ending June 30, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval SEDAR, the electronic filing system for the disclosure documents of issuers across Canada, at 